Cancer Biology
The development of new therapies, especially in the era of targeted treatments and personalized medicine, is driven by understanding the underlying cell biology, molecular biology and biochemistry of tumor cells and their surrounding microenvironments. The Cancer Biology research program represents basic science initiatives of The University of Kansas Cancer Center. Members focus on four discipline-based themes: 1) cancer metastasis and tumor microenvironment; 2) DNA damage/repair and regulation; 3) stem cell biology; and 4) cell signaling pathways.
Members of the Cancer Biology research program aim to understand the molecular mechanisms that define normal and neoplastic cell growth to identify and characterize cells, molecules, pathways and processes that are involved in cancer growth and progression. Their findings can serve as useful biomarkers or new cellular targets for cancer prevention and therapeutics. Members focus their efforts on the cancers that most affect people in the cancer center's catchment area. Overall, their goal is to advance promising basic discoveries into clinical trials.
Cancer Prevention and Control
About 42% of cancer cases and 45% of cancer deaths in the U.S. are believed to be preventable. The Cancer Prevention and Control research program at The University of Kansas Cancer Center brings together researchers focused on identifying new ways to prevent cancer and improve cancer outcomes in the cancer center's catchment area. This includes: 1) identifying population-level cancer risk exposures and developing, testing, and implementing strategies to modify cancer risk behaviors, 2) optimizing risk stratification and developing novel tools to increase evidence-based screening and prevention strategies, and 3) address the survivorship needs of cancer patients through the lifespan by developing, testing, and implementing behavioral, lifestyle, and clinical-support strategies.
Cancer Prevention and Control members represent a rich mix of expertise, including behavioral science, neuroscience, primary care, nursing, oncology, epidemiology, economics, translational biology, pharmacology, communications, biostatistics, and health services research. Their work has led to a better understanding of the cancer control needs in the cancer center's catchment area; improved capacity to analyze the needs of affected and at-risk populations; identification of novel precancerous models and new biomarkers; improved strategies to detect and prevent cancer in high-risk patients; better strategies for the design and delivery of cancer prevention and control messages; and improved delivery of tobacco control, cancer screening, and survivorship programs at the level of both the clinical practice and the community-at-large.
Drug Discovery, Delivery and Experimental Therapeutics
It takes a community of researchers, physicians, patients, and support staff to discover and develop new ways to prevent, detect and treat cancer. The Drug Discovery, Delivery and Experimental Therapeutics research program at The University of Kansas Cancer Center integrates a broad range of research areas that contribute to the discovery of new cancer therapeutic agents as well as novel approaches to effective drug delivery; the development of drug products and diagnostics for the treatment and prevention of cancer; and the evaluation of these medical innovations in hypothesis-driven experimental therapeutics trials.
The Drug Discovery, Delivery and Experimental Therapeutics research program is organized around four themes: 1) Cancer therapeutics Discovery and Development; 2) Cancer therapeutics delivery, 3) Diagnostic and technology development and 4) Experimental Therapeutic Trials focused on improving patient outcomes
The program forms and drives project teams, led by principal investigators and project managers, comprised of basic, translational, and clinical scientists representing multiple disciplines. To bring promising new cancer treatments and diagnostics to patients, members of the Drug Discovery, Delivery and Experimental Therapeutics research program collaborate with industry, academia, government, and disease philanthropy partners.
Obesity, Metabolic Health and Cancer
Obesity is one of the most significant and preventable cancer risk factors and is projected to surpass tobacco as the leading cause of cancer. Poor metabolic health and obesity are linked to the development of at least 13 types of cancer and can negatively impact detection, treatment response, recurrence and survivorship.
The Obesity, Metabolic Health and Cancer research program at The University of Kansas Cancer Center brings together investigators focused on understanding the biological and behavioral drivers of obesity and metabolic dysfunction, and how these factors influence cancer risk and outcomes. Members work across two primary themes: 1) understanding the etiology of obesity and obesity-related cancer risk and progression; and 2) developing interventions that address poor metabolic health and improve outcomes for patients at risk or following a cancer diagnosis.
Program members represent a multidisciplinary mix of expertise, including molecular biologists and biochemists, physiologists, nutritionists, exercise and physical activity researchers, population health researchers, chemists and implementation scientists. Their work spans basic, translational and clinical research, from uncovering molecular mechanisms to testing innovative prevention and treatment strategies.